Long Ideas - Questcor Pharmaceuticals (NASDAQ:QCOR) shares fell roughly 8% on Friday following an update from Aetna (NYSE:AET) regarding the insurer’s coverage of QCOR’s lead product, H.P. Acthar … Continue Reading
Read nowMost Popular - Shares of Questcor Pharmaceuticals (NASDAQ:QCOR) are under pressure Friday, down 10% in morning trading on news that unknown drug company Cerium Pharmaceuticals has received Orphan … Continue Reading
Read nowQuick Picks - Price targets are rising for Questcor Pharmaceuticals (NASDAQ:QCOR) on Wednesday following the company’s third quarter earnings beat. The revised sell-side expectations support PropThink’s target price … Continue Reading
Read nowLong Ideas - Questcor Pharmaceuticals (NASDAQ:QCOR) trounced 3Q 2012 earnings expectations, with reported revenues of $140.3M and adjusted EPS of $0.97 for the period. This compares to Wall Street … Continue Reading
Read nowMost Popular - The Health Care Select Sector SPDR (XLV), the exchange traded fund (ETF) that tracks the Health Care Select Sector Index, gained $0.03 or 0.07% on … Continue Reading
Read nowLong Ideas - Questcor Pharmaceuticals (NASDAQ:QCOR) is scheduled to report third quarter earnings Tuesday after the market closes, and the Wall Street Consensus expects revenues (mostly Acthar Gel) … Continue Reading
Read nowLong Ideas - For most mutual funds, tax-loss selling must be done by the end of Monday. As a result, pressure could come off names that have had … Continue Reading
Read now